Oragenics (NYSE:OGEN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGENGet Free Report) in a report released on Saturday. The firm set a “sell” rating on the stock.

Oragenics Trading Up 42.1 %

Shares of NYSE OGEN opened at $2.33 on Friday. The company has a market capitalization of $10.44 million, a PE ratio of -0.27 and a beta of 0.40. The company’s 50-day moving average is $1.32. Oragenics has a fifty-two week low of $1.00 and a fifty-two week high of $7.74.

Oragenics (NYSE:OGENGet Free Report) last released its quarterly earnings results on Friday, March 29th. The company reported ($5.48) EPS for the quarter.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Stories

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.